--- title: "TGTX.US (TGTX.US) — Related News" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/TGTX.US/news.md" symbol: "TGTX.US" name: "TGTX.US" parent: "https://longbridge.com/en/quote/TGTX.US.md" datetime: "2026-06-13T12:33:20.856Z" locales: - [en](https://longbridge.com/en/quote/TGTX.US/news.md) - [zh-CN](https://longbridge.com/zh-CN/quote/TGTX.US/news.md) - [zh-HK](https://longbridge.com/zh-HK/quote/TGTX.US/news.md) --- # TGTX.US (TGTX.US) — Related News ### [TG Therapeutics Stock Is Surging Today: What's Driving The Action?](https://longbridge.com/en/news/289352299.md) *2026-06-10T15:23:35.000Z* > TG Therapeutics (NASDAQ: TGTX) shares surged 9.50% on Wednesday following positive Phase 1 data for a subcutaneous versi ### [A Look At TG Therapeutics (TGTX) Valuation After Fresh BRIUMVI Clinical And Formulation Milestones](https://longbridge.com/en/news/289276120.md) *2026-06-10T05:23:54.000Z* > TG Therapeutics (TGTX) sees strong stock momentum following positive BRIUMVI Phase 3 ENHANCE data and new subcutaneous f ### [TG Therapeutics Announces Positive Data From BRIUMVI Study, Initiates Phase 2 Trial; Stock Gains](https://longbridge.com/en/news/289203780.md) *2026-06-09T14:09:05.000Z* > TG Therapeutics announced positive Phase 1 data for BRIUMVI in myasthenia gravis patients, with 82% achieving clinical i ### [Analysts highlight top mid-cap growth plays with low valuations](https://longbridge.com/en/news/288935629.md) *2026-06-06T15:33:38.000Z* > Analysts identify mid-cap stocks offering a blend of strong growth and low valuations. Key highlights include American S ### [Top 10 US Stock Gainers (6.3)](https://longbridge.com/en/news/288634789.md) *2026-06-03T22:00:41.000Z* > Abivax SA(ABVX) rose 24.34%, with a trading turnover 610.2 Million USD, and a year-to-date fell 33.2%. Navitas Semicondu ### [TG Therapeutics Flashes An Early Buy Signal — What Drove The Bullish Jump](https://longbridge.com/en/news/288635239.md) *2026-06-03T21:46:44.000Z* > TG Therapeutics stock surged following news that its subcutaneous injection of Briumvi demonstrated safety comparable to